昭衍新药
(603127)
| 流通市值：120.55亿 | | | 总市值：143.30亿 |
| 流通股本：6.30亿 | | | 总股本：7.49亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 287,337,235.01 | 2,018,333,771.81 | 1,335,156,050.4 | 849,356,544.11 |
| 营业收入 | 287,337,235.01 | 2,018,333,771.81 | 1,335,156,050.4 | 849,356,544.11 |
| 二、营业总成本 | 288,252,886.21 | 1,763,748,341.31 | 1,227,734,251.03 | 753,062,458.9 |
| 营业成本 | 205,132,917.71 | 1,444,560,234.36 | 968,251,629.5 | 591,423,436.78 |
| 税金及附加 | 1,352,112.14 | 8,981,402.37 | 6,894,612.65 | 5,384,649.37 |
| 销售费用 | 6,079,268.59 | 27,881,056.45 | 19,402,507.49 | 12,163,059.33 |
| 管理费用 | 71,784,152.89 | 289,180,575.62 | 236,735,760.07 | 156,350,663.29 |
| 研发费用 | 23,027,883.99 | 92,918,280.66 | 71,085,657.06 | 47,839,663.09 |
| 财务费用 | -19,123,449.11 | -99,773,208.15 | -74,635,915.74 | -60,099,012.96 |
| 其中:利息费用 | 521,186.18 | 2,448,073.47 | 1,827,953.64 | 1,248,564.49 |
| 其中:利息收入 | 21,160,369.25 | 103,230,766.43 | 82,526,990.66 | 61,632,134.02 |
| 加:公允价值变动收益 | 65,875,504.16 | -127,048,597.78 | -190,401,449.68 | -257,190,170.68 |
| 加:投资收益 | 1,235,855.96 | 36,011,545.69 | 31,620,189.62 | 28,019,180.74 |
| 资产处置收益 | - | -48,130.43 | -468,673.84 | -468,673.84 |
| 资产减值损失(新) | -32,494,609.52 | -66,540,016.67 | -25,480,216.62 | -45,213,931.95 |
| 信用减值损失(新) | 10,411,088.36 | -19,140,159.62 | -11,477,062.92 | -8,166,657.57 |
| 其他收益 | 5,270,400.41 | 26,527,237.43 | 19,124,400.35 | 9,571,426.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 49,382,588.17 | 104,347,309.12 | -69,661,013.72 | -177,154,741.3 |
| 加:营业外收入 | 48,408.25 | 223,456.84 | 96,166.74 | 109,059.02 |
| 减:营业外支出 | 47,246.62 | 531,692.34 | 327,422.81 | 305,425.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 49,383,749.8 | 104,039,073.62 | -69,892,269.79 | -177,351,107.31 |
| 减:所得税费用 | 8,264,284.55 | 34,284,009.72 | 4,351,740.15 | -5,112,791.17 |
| 六、净利润 | 41,119,465.25 | 69,755,063.9 | -74,244,009.94 | -172,238,316.14 |
| 持续经营净利润 | 41,119,465.25 | 69,755,063.9 | -74,244,009.94 | -172,238,316.14 |
| 归属于母公司股东的净利润 | 41,119,492.23 | 74,075,384.59 | -70,307,075.11 | -169,742,640.65 |
| 少数股东损益 | -26.98 | -4,320,320.69 | -3,936,934.83 | -2,495,675.49 |
| (一)基本每股收益 | 0.05 | 0.1 | -0.09 | -0.23 |
| (二)稀释每股收益 | 0.05 | 0.1 | -0.09 | -0.23 |
| 八、其他综合收益 | -766,939.36 | -51,041,084.41 | -4,859,185.75 | 3,024,917.86 |
| 归属于母公司股东的其他综合收益 | -766,939.36 | -51,041,084.41 | -4,859,185.75 | 3,024,917.86 |
| 九、综合收益总额 | 40,352,525.89 | 18,713,979.49 | -79,103,195.69 | -169,213,398.28 |
| 归属于母公司股东的综合收益总额 | 40,352,552.87 | 23,034,300.18 | -75,166,260.86 | -166,717,722.79 |
| 归属于少数股东的综合收益总额 | -26.98 | -4,320,320.69 | -3,936,934.83 | -2,495,675.49 |
| 公告日期 | 2025-04-29 | 2025-03-29 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |